John W Kozarich sold $89k of LGND
director at LIGAND PHARMACEUTICALS INC. 467 shares at an average of $191.05, traded Nov 3, 2025, filed Nov 5, 2025.
Score components
- +15RoleDirector
- +9Trade size$89k at market
- 0Share of holdings soldSold 1.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.9%, 3m +4.2%, 6m +22.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-25-000096, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | SOpen-market sale Common Stock10b5-1 | -84 | $189.00 | $16k | 44,971 | Nov 5, 2025 |
| Nov 3, 2025 | SOpen-market sale Common Stock10b5-1 | -49 | $190.26 | $9,323 | 44,922 | Nov 5, 2025 |
| Nov 3, 2025 | SOpen-market sale Common Stock10b5-1 | -207 | $191.25 | $40k | 44,715 | Nov 5, 2025 |
| Nov 3, 2025 | SOpen-market sale Common Stock10b5-1 | -127 | $192.38 | $24k | 44,588 | Nov 5, 2025 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 47Moderate | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $9.2M 31,641 shares | -53% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $2.1M 7,138 shares | -64% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -11% | |
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.6M 5,000 shares | -11% | |
| 34Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $545k 2,145 shares | -6% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $1.7M 6,461 shares | -56% | |
| 55Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.